reports
Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclus...
Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclusive Pilot Program For ilumen™ SYDNEY, Australia and MINNEAPOLIS, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company announces that it has signed an exclusive agreement with AIAA to undertake a pilot program for the latest release of its corporate health program, ilumen™. AIAA is one of Australia’s leading life insurers, offering a range of products that protect the financial health and wellbeing of more than 4 million Australians. AIAA is ...
Medibio Appoints Global Healthcare & Medical Device Leader as CEO and ...
Medibio Appoints Global Healthcare & Medical Device Leader as CEO and Managing Director SYDNEY, Australia and MINNEAPOLIS, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, announces the appointment of David B. Kaysen as CEO and Managing Director. Mr. Kaysen brings more than 35 years of experience leading and managing both domestic and international emerging growth companies. He has achieved consistent and solid results with bio-pharmaceutical, medical device, and clinical software/IT companies. He is exper...
Medibio Market Update
Medibio Market Update SYDNEY, Australia and MINNEAPOLIS, Minn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB)(OTCQB: MDBIF), a mental health technology company, today shares a market update to the recent quarterly update. ISO 13485 CertificationThis week the company completed the annual audit process for certification of the Company’s Quality Management System. The audit was conducted by DQS Med, the Notified Body appointed to assess our compliance. There were no major or minor findings, providing further evidence of the stability of our quality s...
Medibio Limited Quarterly ASX Update and Cashflows
Medibio Limited Quarterly ASX Update and Cashflows Quarterly Update and Message from Medibio Limited SYDNEY, Australia and MINNEAPOLIS, Minn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB)(OTCQB: MDBIF), a mental health technology company provides the following quarterly update: Key highlights from the quarter Announced clinical study results - showing an improvement of more than 20% to current diagnostic standard- Achievement of 70% accuracy, 70% sensitivity and 71% specificity results - demonstrating utility as diagnostic aide and long-term monitor...
Medibio Signs ilumenâ„¢ Corporate Contract with a Large Australian Em...
Medibio Signs ilumen™ Corporate Contract with a Large Australian Employer SYDNEY, Australia and MINNEAPOLIS, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), a mental health technology company, announces a contract for the latest release of its corporate health program, ilumen™. ilumen™ is unique to the corporate health market as it integrates unique and proprietary objective biometrics with subjective assessments. Users can access and monitor this data from their personal devices, measuring and tracking biometrics through the use of wear...
Receipt of $3,146,835 R&D Tax Incentive Refund
Receipt of $3,146,835 R&D Tax Incentive Refund SYDNEY, Australia and MINNEAPOLIS, Minn., Oct. 15, 2018 (GLOBE NEWSWIRE) -- (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, is pleased to announce that it has received $3,146,835 from the Australian Taxation Office under the Research and Development Tax Incentive Program. The cash refund is related to expenditure on eligible Australian and Overseas R&D activities conducted during the financial year ended 30 June 2018. About Medibio Limited Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology c...
Medibio Technology Honored with Two Presentations at Mayo Clinic Conve...
Medibio Technology Honored with Two Presentations at Mayo Clinic Convergence Neuroscience 2018 SYDNEY, Australia and MINNEAPOLIS, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, is happy to announce that two clinical abstracts by Dr. Archie Defillo et al. have been accepted for presentation as part of the Mayo Clinic Convergence Neuroscience 2018 Course. Both presentations are based on the recently completed DX04 clinical study. Dr. Archie Defillo, Chief Medical Officer at Medibio, will share the followin...
Medibio Provides Updated Company Presentation
Medibio Provides Updated Company Presentation SYDNEY, Australia and MINNEAPOLIS, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, is pleased to release an updated company presentation, which is attached to this announcement. The presentation will be used for a series of meetings in the coming weeks. About Medibio LimitedMedibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and ma...
Medibio Releases Corporate Health Product, ilumenâ„¢
Medibio Releases Corporate Health Product, ilumen™ SYDNEY, Australia and MINNEAPOLIS, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, today announced the release of ilumen™, its product and platform for corporate customers. ilumen™ is a corporate wellness product providing employers the ability to offer biometric analysis and objective, data-driven feedback along with a mental wellness assessment to their employees. The upgraded platform allows employees to access and monitor this data from their personal...
Medibio Named Finalist for Prestigious Optus My Business Award
Medibio Named Finalist for Prestigious Optus My Business Award The awards are the longest-standing business awards program in Australia, identifying and acknowledging the achievements of Australia’s best business operators MINNEAPOLIS, Minn. and SYDNEY, Australia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF) has been shortlisted as a finalist in the Health Services Business of the Year category at the 2018 Optus My Business Awards, the premier event of the year for small and medium-sized enterprises. is a mental health technology compa...
Medibio Announces Executive Leadership Changes
Medibio Announces Executive Leadership Changes SYDNEY, Australia and MINNEAPOLIS, Minn., Sept. 21, 2018 (GLOBE NEWSWIRE) -- The Board of Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), today announced several changes to the Company’s executive leadership team. Medibio is pleased to announce the appointment of Jennifer Solitario as Senior Vice President of Corporate Health. Ms. Solitario is a proficient leader with more than 20 years of experience in the health insurance industry. Working as Executive General Manager Health and Wellness at HBF Health, Ms. Solitario oversaw b...
Medibio Provides Market Update
Medibio Provides Market Update SYDNEY, Australia and MINNEAPOLIS, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), a mental health technology company, today provides a market update to the last quarterly report. Our purpose at Medibio is clear: To improve the screening, diagnosis, monitoring, and management of mental health. We believe in our innovative technology and remain steadfast and focused on our mission to identify the link between physiological measures and mental health. Medibio is developing modern technological tools for profe...
Medibio Clinical Study Shows Over 20% Improvement to Current Diagnosti...
Medibio Clinical Study Shows Over 20% Improvement to Current Diagnostic Standard Highlights: Global 230 patient (8 sites) study confirms Medibio’s Depression Diagnostic Aide (DX04)With 70% accuracy, 70% sensitivity and 71% specificity results demonstrate utility in long-term monitoringStudy results support the FDA DeNovo submissionDiagnostic algorithm designed to provide mental health practitioners with an objective technology to aide in assessment of depressionDemonstrated positive predictive value up to 72% and negative predictive value up to 78% SYDNEY, Australia and MINNEA...
Departure of Managing Director & Chief Executive Officer
Departure of Managing Director & Chief Executive Officer SYDNEY, Australia and MINNEAPOLIS, Aug. 29, 2018 (GLOBE NEWSWIRE) -- The Board of Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), today announced that Mr. Jack Cosentino will cease as Managing Director and Chief Executive Officer of the Company. His departure is effective from August 28, 2018. Mr. Cosentino was appointed Managing Director and Chief Executive Officer on February 16, 2017. Medibio further advises that Mr. Brian Mower has been appointed Interim CEO effective as at August 28, 2018. Mr. Mower is the Comp...
Medibio Submits FDA De Novo Application
Medibio Submits FDA De Novo Application SYDNEY, Australia and MINNEAPOLIS, July 16, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company, today announced the U.S. Food and Drug Administration (FDA) De Novo submission for its Clinical Decision Support System (System) and the first of many modules that addresses the aid to the diagnosis of mental health disorders. The formal submission to the FDA was completed on Friday, July 13, following the successful 230-person clinical study at eight clinical sites and an in-person mee...
Peer-reviewed Neurology Publication on Medibio Science
Peer-reviewed Neurology Publication on Medibio Science SYDNEY, Australia and MINNEAPOLIS, June 26, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, announces that a clinical article by Defillo et al. titled “Physiological Differences between Mood Disorder Phenotypes Based on Heart Rate Variability” has been accepted for publication in EC Neurology, an internationally peer-reviewed journal. Research was based on the 24-hour heart rate patterns of 301 consecutive patients with diagnosis of either normal, anxiety, de...
Medibio Receives TGA Approval
Medibio Receives TGA Approval SYDNEY, Australia and MINNEAPOLIS, June 19, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company, announced today it has received confirmation that the Company’s Depression Diagnostic Aide (DDA) and Mental Health Monitoring Platform (MHM) have been included on the register of Australian Therapeutic Goods Administration (ATGA). Medibio’s DDA and MHM technology underpin the Company’s Mental Index application and Logics platform. The Company’s regulatory validation now includes both the CE...
Medibio Broadens Opportunities with Compatibility to Fitbit Wearable D...
Medibio Broadens Opportunities with Compatibility to Fitbit Wearable Devices for Mental Health Measurement Fitbit joins Apple Watch, Garmin and others allowing users to help process biometric data for an objective view of mental health SYDNEY, Australia and MINNEAPOLIS, June 13, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (ASX:MEB) (OTCQB:MDBIF), the world leader in objective measurement technology for mental health, has recently enhanced the compatibility of its mobile app product to accept data from Fitbit devices equipped with heart rate monitors. The mobile app, named Medibio Info...
A director bought 100,000 shares at 0.370AUD and
A director at Medibio Limited bought 100,000 shares at 0.370AUD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
LifeQ and Medibio to Deliver Scalable Mental Wellness Diagnostic and M...
LAS VEGAS--(BUSINESS WIRE)-- Medibio and LifeQ today announced at CES a partnership towards delivering mental wellness diagnostic and management solutions to a wide range of users through insurance and corporate programs. Mental health and wellness is a significant issue globally. Left untreated, chronic stress and depression can result in serious health conditions including anxiety, insomnia, high blood pressure and a weakened immune system, contributing to the development of chronic diseases, such as cardiovascular disease, diabetes...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.